Search This Blog

Monday, July 29, 2019

CRISPR Therapeutics EPS misses by $1.10, misses on revenue

CRISPR Therapeutics (NASDAQ:CRSP): Q2 GAAP EPS of -$1.01 misses by $1.10.
Revenue of $0.32M (-70.6% Y/Y) misses by $47.25M.
Shares -1.71%.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)